Hualan Biological's Subsidiary Receives IND Approval for Recombinant Anti-BCMA/CD3 Bispecific Antibody Injection for Relapsed or Refractory Multiple Myeloma

Zhitong Finance APP reported that Hualan Biological Engineering, Inc. (002007.SZ) announced that Hualan Genetic Engineering (Henan) Co., Ltd. (hereinafter referred to as "Genetic Company"), a wholly-owned subsidiary of its participating company Hualan Genetic Engineering Co., Ltd., has received the "Drug Clinical Trial Approval Notice" (Notice No.: 2023LP01285) issued by the National Medical Products Administration. The clinical trial application for "Recombinant Anti-BCMA and CD3 Bispecific Antibody Injection" submitted by the Genetic Company has been approved: After review, the Recombinant Anti-BCMA and CD3 Bispecific Antibody Injection submitted by the Genetic Company meets the relevant requirements for drug registration, and is approved to conduct clinical trials for relapsed or refractory multiple myeloma. The Genetic Company will carry out relevant clinical trial work as required by the Drug Clinical Trial Approval Notice.